Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model

Naviaux et al.
Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model

Jane C Naviaux, Lin Wang, Kefeng Li, A Taylor Bright, William A Alaynick, Kenneth R Williams, Susan B Powell, and Robert K Naviaux

Abstract

Background: This study was designed to test a new approach to drug treatment of autism spectrum disorders (ASDs) in the Fragile X (Fmr1) knockout mouse model.

Methods: We used behavioral analysis, mass spectrometry, metabolomics, electron microscopy, and western analysis to test the hypothesis that the disturbances in social behavior, novelty preference, metabolism, and synapse structure are treatable with antipurinergic therapy (APT).

Results: Weekly treatment with the purinergic antagonist suramin (20 mg/kg intraperitoneally), started at 9 weeks of age, restored normal social behavior, and improved metabolism, and brain synaptosomal structure. Abnormalities in synaptosomal glutamate, endocannabinoid, purinergic, and IP3 receptor expression, complement C1q, TDP43, and amyloid β precursor protein (APP) were corrected. Comprehensive metabolomic analysis identified 20 biochemical pathways associated with symptom improvements. Seventeen pathways were shared with human ASD, and 11 were shared with the maternal immune activation (MIA) model of ASD. These metabolic pathways were previously identified as functionally related mediators of the evolutionarily conserved cell danger response (CDR).

Conclusions: The data show that antipurinergic therapy improves the multisystem, ASD-like features of both the environmental MIA, and the genetic Fragile X models. These abnormalities appeared to be traceable to mitochondria and regulated by purinergic signaling.

Keywords: Autism spectrum disorders, Purinergic signaling, Antipurinergic therapy (APT), Mitochondria, Metabolism, Metabolomics, Fragile X syndrome, Genetics, Environment, Maternal immune activation (MIA), Cell danger response (CDR)

Background

Autism spectrum disorders (ASDs) now affect 1% to 2% of children in the United States [1]. Genetic [2-4], environmental [5,6], and metabolic [7] factors can contribute to the risk of ASD to different extents in each affected child. We have previously shown that antipurinergic therapy reverses the behavioral and metabolic abnormalities in the maternal immune activation (MIA) mouse model of ASD in juveniles [8] and adults [9]. The MIA and Fragile X models have been considered to be mechanistically distinct examples of environmental and genetic causes of ASD, respectively. However, in our MIA study we found the first of several emerging connections. The Fmr1 protein (FMRP) was downregulated by 50%, and antipurinergic therapy with suramin restored normal FMRP and normal behaviors in the MIA model [8]. FMRP is an mRNA and ribosome [10] binding protein that inhibits the expression of several key inflammatory proteins and cytokines, and binds to several DNA repair proteins involved in cell stress and defense [11]. Genetic loss of FMRP expression leads to Fragile X Syndrome, the most common
single-gene cause of intellectual disability [12]. The Fmr1 knockout is the oldest, and one of the most studied genetic mouse models used in autism research [13]. In our previous work we found that disturbances in purine metabolism and purinergic signaling were robust features and effective targets for treatment in the environmental MIA mouse model of autism [8,9]. Interestingly, the first genetic causes of autism identified were traced to abnormalities in purine and pyrimidine metabolism [14,15]. These observations led us to test the role of purinergic signaling in a genetic mouse model of ASD. We selected the Fragile X model to test the hypothesis that abnormalities in purinergic signaling might underlie both the environmental MIA and genetic Fragile X models.

Suramin is a well-known and well-studied competitive inhibitor of purinergic signaling [16]. It has been used medically for the treatment of African sleeping sickness (trypanosomiasis) since shortly after it was first synthesized in 1916. Its antipurinergic actions were discovered in 1988, after a search for inhibitors of ATP-mediated P2X and P2Y signaling [17]. Suramin has many other actions [18], however, metabolomic studies have shown that the expression of purinergic receptors is altered [8], and purine metabolism is the top ranked biochemical pathway that is changed by treatment in the MIA model of ASD [9]. We refer to the use of suramin and related purinergic antagonists as antipurinergic therapy (APT). In the present work, we tested the hypothesis that APT will improve behavior, metabolism, and synaptic abnormalities in the Fragile X mouse model, even in the face of a permanent, gene-coded absence of the Fragile X protein.

**Methods**

**Mouse strains**

We evaluated the Fragile X (Fmr1) knockout on the FVB strain background. It has the genotype: FVB.129P2-Pde6b+ Tyr+c-ch Fmr1tm1Cgr/J (Jackson Stock # 004624). The Fmr1tm1Cgr allele contains a neomycin resistance cassette replacing exon 5 that results in a null allele that makes no FMR mRNA or protein. The control strain used has the genotype: FVB.129P2-Pde6b+ Tyr+c-ch/AntJ (Jackson Stock # 004828). In contrast to the white coat color of wild-type FVB mice, these animals had a chinchilla (Tyr+c-ch) gray coat color. The wild-type Pde6b locus from the 129P2 ES cells corrects the retinal degeneration phenotype that produces blindness by 5 weeks of age in typical FVB mice. The Fmr1 locus is X-linked, so males are hemizygous and females are homozygous for the knockout. We also performed metabolomic analysis on Fmr1 knockout mice on the C57BL/6J (B6) background to refine our understanding of which metabolic disturbances were directly related to the Fmr1 knockout, and which were the result of changes in genetic background. For these studies we studied the same Fmr1tm1Cgr knockout allele bred on the C57BL/6J background. These animals had the genotype: B6.129P2-Fmr1tm1Cgr/J (Jackson Stock# 003025). The standard C57BL/6J strain (Jackson Stock# 000664) was used as a control for the B6 metabolic studies.

**Animals, husbandry, and drug treatment**

All studies were conducted at the University of California, San Diego (UCSD) in facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) under UCSD Institutional Animal Care and Use Committee (IACUC)-approved animal subjects protocols, and followed the National Institutes of Health (NIH) Guidelines for the use of animals in research. Five-week-old male mice were obtained from Jackson Laboratories (Bar Harbor, ME), identified by ear tags, placed in cages of two to four animals, and maintained on ad libitum Harlan Teklad 8604 mouse chow (14% fat, 54% carbohydrate, 32% protein) and water. Animals were housed in a temperature (22°C to 24°C) and humidity (40% to 55%) controlled vivarium with a 12-h light-dark cycle (lights on at 07:00). No mice were housed in isolation. Beginning at 9 weeks of age, animals received weekly injections of either saline (5 μL/g ip) or suramin (hexasodium salt, 20 mg/kg ip; Tocris Cat #1472).

**Behavioral analysis**

Behavioral testing began at 13 weeks of age, after 1 month of weekly antipurinergic therapy with suramin. Mice were tested in social approach, T-maze, locomotor activity, marble burying, acoustic startle, and prepulse inhibition paradigms as follows. The ages at the time of testing are noted in the figure legends. For a complete description of the behavioral paradigms see Full Methods Online. **Social Preference and Social Novelty.** Social behavior was tested as social preference as previously described [9], with the addition of a third phase with a second novel mouse to interrogate social novelty [19]. **T-Maze.** Novelty preference was tested as spontaneous alternation behavior in the T-maze as previously described [9]. **Marble Burying.** Marble burying behavior was measured over 30 min by a modification of methods used by Thomas et al. [20]. **Locomotor Activity.** Locomotor activity, hyperactivity (total distance traveled), center entries, holepoke exploration, and vertical investigation (rearing) behaviors were quantified by automated beam break analysis in the mouse behavioral pattern monitor (mBPM) as previously described [21]. **Acoustic Startle and Prepulse Inhibition.** Sensitivity to acoustic startle and prepulse inhibition of the startle reflex were measured by automated testing in commercial startle chambers as previously described [22].
**Body temperature measurements**

A BAT-12 Microprobe digital thermometer and RET-3 mouse rectal probe (Physitemp Instruments, Clifton, NJ, USA) were used to obtain rectal core temperatures to a precision of +/−0.1°C, as previously described [8]. Care was taken to measure temperatures ≥2 days after cage bedding changes, and to avoid animal transport stress immediately prior to measurement in order to avoid stress-induced hyperthermia [23]. Temperatures were measured between 09:00 and 12:00 each day.

**Synaptosome isolation and ultrastructure**

Animals were sacrificed at 25 weeks of age, after receiving 16 weeks of treatment with suramin or saline. Cerebral samples were collected, homogenized, and synaptosomes isolated by discontinuous Percoll gradient centrifugation, drop dialyzed, glutaraldehyde fixed, post-fixed in osmium tetroxide, embedded, sectioned, and stained with uranyl acetate for transmission electron microscopy (TEM) as previously described [8]. Samples from the FVB control animals (+/- suramin) were not available for study by either electron microscopy or western analysis. Therefore, we report only the effects of suramin on the two groups of Fmr1 knockout animals (KO-saline and KO-suramin). N = 3 animals/group. Four to six TEM images were collected from each sample. One 5,800× survey image, and three to five images of informative fields at 34,000× to 64,000× were collected with internal scale bars for dimensional control. Qualitatively representative images were reported.

**Western blot analysis**

Twenty micrograms of cerebral synaptosomal protein was loaded in SDS-polyacrylamide gels (NuPage 4-12% gradient, Bis-Tris Gels) and transferred to PVDF membranes as previously described [8]. The blots were first stained with 0.1% Ponceau S in 5% acetic acid for 10 min, washed, scanned, and the transfer efficiency was quantified by densitometry. Blots were then blocked with 5% skim milk in tris-buffered saline with 0.1% Tween 20 (TBST) for 1 h at room temperature with shaking. Primary antibodies were obtained commercially as 1 mg/mL stocks (see Additional file 1: Table S1 for source details). These were diluted 1:500 to 1:10,000 (final concentrations of 2000 ng/mL to 100 ng/mL; Additional file 1: Table S1) in 5% BSA or 5% skim milk in TBS with 0.1% Tween 20 and optimized for each target to achieve signals in the linear range using dilutions (5 to 20 μg/lane) of cerebral synaptosomes prepared from C57BL/6J control animals. When monoclonal antibodies to a peptide of the target protein were used, peptide was pre-incubated with primary antibody to confirm specificity. When blocking peptides were not available, signal specificity was determined by correspondence of the observed band pattern and molecular weight to the published or manufacturer values for each target protein. Only antibodies that identified specific target bands in cerebral synaptosomes from age-matched control animals were used. Blots were probed with the optimized dilution of primary antibody overnight in the cold room (4°C). Secondary antibodies conjugated to horseradish peroxidase were obtained from Pierce (Rockford, IL, USA) diluted 1:5,000 (200 ng/mL) to 1:20,000 (50 ng/mL) in 3% skim milk-TBST. The blots were probed for 1 h at room temperature prior to final wash and signal development by enhanced chemiluminescence (ECL) or SuperSignal West Femto chemiluminescent substrate (Thermo, Cat# 34095), then quantified by densitometry. At least five animals per group were analyzed. We evaluated the cerebral synaptosome expression of 54 proteins (Additional file 1: Table S1).

**Metabolomics**

Broad spectrum analysis of 673 targeted metabolites from 60 biochemical pathways was performed as described [9], with minor modifications. Samples were analyzed on an AB SCIEX QTRAP 5500 triple quadrupole mass spectrometer equipped with a Turbo V electrospray ionization (ESI) source, Shimadzu LC-20A UHPLC system, and a PAL CTC autosampler (AB ACIX, Framingham, MA, USA). Whole blood was collected 3 to 4 days after the last weekly dose of suramin (20 mg/kg ip) or saline (5 μL/g ip), after light anesthesia in an isoflurane (Med-Vet International, Mettawa, IL, USA, Cat# RXISO-250) drop jar, into BD Microtainer tubes containing lithium heparin (Becton Dickinson, San Diego, CA, USA, Ref# 365971) by submandibular vein lancet [24]. Plasma was separated by centrifugation at 600g x 5 min at 20°C within 1 h of collection. Fresh lithium-heparin plasma was transferred to labeled tubes for storage at -80°C for analysis. Typically 45 μL of plasma was thawed on ice and transferred to a 1.7 mL Eppendorf tube. A total of 2.5 μL of a cocktail containing 35 commercial stable isotope internal standards, and 2.5 μL of 310 stable isotope internal standards that were custom-synthesized in E. coli and S. cerevisiae by metabolic labeling with 13C-glucose and 13C-bicarbonate, were added, mixed, and incubated for 10 min at room temperature to permit small molecules and vitamins in the internal standards to associate with plasma binding proteins. Macromolecules (protein, DNA, RNA, and so on) were precipitated by extraction with 4 volumes (200 μL) of cold (-20°C), acetonitrile:methanol (50:50) (LCMS grade, Cat# LC1015-2.5 and GC230-4, Burdick & Jackson, Honeywell), vortexed vigorously, and incubated on crushed ice for 10 min, then removed by centrifugation at 16,000 g x 10 min at 4°C. The supernatants containing the extracted metabolites and internal standards in the resulting 40:40:20 solvent mix of acetonitrile:methanol:
water were transferred to labeled cryotubes and stored at -80°C for LC-MS/MS (liquid chromatography-tandem mass spectrometry) analysis.

LC-MS/MS analysis was performed by multiple reaction monitoring (MRM) under Analyst v1.6.1 (AB SCIEX, Framingham, MA, USA) software control in both negative and positive mode with rapid polarity switching (50 ms). Of the 673 metabolites targeted, 477 metabolites were measured by scheduled MRM in the first injection, and 196 metabolites were measured by scanning MRM in a second injection. Nitrogen was used for curtain gas (set to 30), collision gas (set to high), ion source gas 1 and 2 (set to 35). The source temperature was 500°C. Spray voltage was set to -4,500 V in negative mode and 5,500 V in positive mode. The values for Q1 and Q3 mass-to-charge ratios (m/z), declustering potential (DP), entrance potential (EP), collision energy (CE), and collision cell exit potential (CXP) were determined and optimized for each MRM for each metabolite. Ten microliters of extract were injected into a 250 × 2 mm, 5 μm Luna NH2 aminopropyl HPLC column (Phenomenex, Torrance, CA, USA) held at 25°C for chromatographic separation. The mobile phase was solvent A: 95% water with 23.18 mM NH4OH (Sigma-Aldrich, St. Louis, MO, USA, Fluka Cat# 17837-100ML), 20 mM formic acid (Sigma, Fluka Cat# 09676-100ML) and 5% acetonitrile (pH 9.44); solvent B: 100% acetonitrile. Separation was achieved using the following gradient: 0 min 95% B, 3 min 95% B, 3.1 min 80% B, 6 min 80% B, 6.1 min 70% B, 10 min 70% B, 18 min 2% B, 27 min 0% B, 32 min 0% B, 33 min 100% B, 36.1 95% B, 40 min 95% B end. The flow rate was 300 μL/min. All the samples were kept at 4°C during analysis. The chromatographic peaks were identified using MultiQuant (v3.0, AB SCIEX), confirmed by manual inspection, and the peak areas integrated. The median of the peak area of stable isotope internal standards was calculated and used for the normalization of metabolites concentration across the samples and batches. Prior to multivariate and univariate analysis, the data were log-transformed.

Metabolic pathway visualization in cytoscape
We constructed a rendering of mammalian intermediary metabolism in Cytoscape v 3.1.1 (http://www.cytoscape.org/). Pathways represented in the network for Fragile X syndrome included the 20 metabolic pathways and the 58 metabolites that were altered by antipurinergic therapy with suramin (VIP scores > 1.5). Nodes in the Cytoscape network represent metabolites within the pathways and have been colored according to the z-score. The z-score was computed as the arithmetic difference between the mean concentration of each metabolite in the KO-Sur treatment group and the KO-Sal control group, divided by the standard deviation in the controls. Node colors were arranged on a red-green color scale with green representing ≤ -2.00 z-score, red representing ≥ +2.00 z-score, and with a zero (0) z-score represented as white. The sum of the VIP scores of those metabolites with VIP scores >1.5 for each metabolic pathway is displayed next to the pathway name.

Data analysis
Group means and standard error of the means (SEM) are reported. Behavioral data were analyzed by two-way ANOVA and one-way ANOVAs (GraphPad Prism 5.0d, GraphPad Software Inc., La Jolla, CA, USA, or Stata/SE v12.1, StataCorp, College Station, TX, USA). Pair-wise post hoc testing was performed by the method of Tukey or Newman-Keuls. Significance was set at \( P < 0.05 \). Metabolomic data were log-transformed and analyzed by multivariate partial least squares discriminant analysis (PLSDA) in MetaboAnalyst [25]. Metabolites with variable importance in projection (VIP) scores greater than 1.5 were considered significant.

Results
Confirmation of Fragile X protein knockout
We confirmed the absence of Fragile X protein (FMRP) expression in Fmr1 knockout mice, and its presence in FVB and C57BL/6J controls by western blot analysis before phenotyping the Fmr1 knockout animals used in this study (Additional file 1: Figure S1).

Restoration of normal social behavior
Altered social behavior is a key measure of autism-like features in mouse models of autism. In the Fragile X knockout genetic model of autism, it has also proven to be one of the most reproducible paradigms across different studies reported in the literature [26]. We found that Fmr1 null males showed a 26% reduction in social preference, as measured by the time spent interacting with a stranger mouse compared to an inanimate object. There was also a 35% reduction in social novelty, as measured by the time spent interacting with a novel mouse compared to a familiar mouse. This altered social behavior was corrected by antipurinergic therapy with suramin (Figure 1A-D).

Restoration of spontaneous alternation in the T-maze
Novelty preference is an innate feature of normal rodent [27] and human [28] behavior, and a predictor of socialization and communication growth in children with ASD [29]. The loss or suppression of novelty preference in children with ASD is associated with the phenomenon known as insistence on sameness [30]. We estimated preference for novelty as spontaneous alternation behavior in the T-maze [9]. The T-maze can also be used to estimate spatial
working memory, especially when food motivated [31]. We did not use the food-motivated variation in our study. We found that the Fmr1 null mice showed deficient novelty preference as reflected by chance (near 50%) spontaneous alternation behavior. These deficits were normalized by suramin treatment (Figure 1E). Fragile X knockout mice were no different from controls in latency to choice (data not shown).

Figure 1 ASD-like symptoms were improved by antipurinergic therapy. (A) Social preference measured as percent time. Fmr1 knockouts treated with saline showed significant deficits in social preference compared to wild-type controls (F(3,38) = 5.94, P = 0.002) and suramin corrected this (P <0.05). (B) Social novelty measured as percent time. Fmr1 knockouts treated with saline also showed significant deficits in social novelty. (F(3,38) = 3.49, P = 0.025) and suramin restored this (P <0.05). (C) Social preference as absolute time spent interacting socially. Fmr1 knockouts were less social than wild-type controls and suramin treatment corrected this (cup F(1,76) = 56.5, P = 0.0001; cup x group F(3,76) = 3.55, P = 0.018). (D) Social novelty as absolute time interacting with a novel mouse. Fmr1 knockouts showed decreased novelty preference and suramin improved this (social stimulus main effect F(1,76) = 86; P = 0.004; social stimulus x group F(3,76) = 3.1, P = 0.032. Age 17 weeks; N = 9-12 per group for Social Preference/Social Novelty test. (E) Restoration of spontaneous alternation in the T-maze. Suramin improved spontaneous alternation in the Fmr1 knockouts, but had no effect on FVB controls (F(3,41) = 16.6; P <0.0001). Age 13 weeks; N = 11-12 per group. (F) Restoration of normal marble burying. Fmr1 knockouts treated with saline buried fewer marbles compared to controls (F(3,37) = 3.15; P = 0.037) and suramin corrected this (P <0.05). Age 16 weeks; N = 9-12 per group. (G) Relative hypothermia in the Fragile X model and correction with suramin. Fmr1 knockout animals treated with saline had core temperatures that were 0.5-0.7°C lower than wild-type FVB controls (F(3,41) = 10.45, P <0.0001). Suramin restored normal body temperature in Fmr1 knockouts (P = 0.001). Age 15 weeks, N = 11-12 per group. Values are expressed as means +/- SEM.
Restoration of marble burying behavior

We measured marble burying as a measure of normal rodent digging behavior. Marble burying has sometimes been considered a measure of anxiety, however, comprehensive genetic and behavioral studies have shown that marble burying is a normal mouse behavior that is genetically determined [20]. We found that marble burying was diminished 38% in Fragile X knockout mice. Suramin improved this (KO-Sal v KO-Sur; Figure 1F).

Restoration of normal body temperature

Fmr1 knockout mice displayed relative hypothermia of approximately 0.5°C to 0.7°C below the basal body temperature of the FVB controls (Figure 1G). This relative hypothermia was lost in stressed animals (data not shown). The maternal immune activation (MIA) mouse model showed a similar mild reduction in body temperature [8]. Normal basal body temperature was restored by antipurinergic therapy with suramin. Suramin had no effect on the body temperature of control animals (WT-Sal vs WT-Sur, Figure 1G).

Synaptosomal ultrastructure and protein expression

Our previous studies showed synaptic ultrastructural abnormalities in the MIA mouse model that were corrected by antipurinergic therapy [8]. In that study, the animals with ASD-like behaviors were found to have abnormal synaptosomes containing an electron dense matrix and brittle or fragile and hypomorphic post-synaptic densities. In the present study of the Fragile X model, saline-treated Fmr1 knockout mice had cerebral synaptosomes that were near-normal in appearance, with an electron lucent matrix (Figure 2B, marked with an asterisk), and normal appearing post-synaptic densities (Figure 2B, marked with an arrow). We did not investigate dendritic spine densities in this study.

Cerebral synaptosomal protein analysis

We found that 17 of 54 proteins we interrogated in cerebral synaptosomes (see Additional file 1: Table S1) were changed by antipurinergic therapy with suramin in the Fragile X model (Figures 3 and 4; KO-Sur vs. KO-Sal). As a treatment study, we focused on the effect of suramin in the Fmr1 knockout mice only. The current study did not compare knockout brain protein levels to littermate FVB controls (see Methods).

Synaptosomal PI3K/AKT/GSK3β pathway

The PI3/AKT/GSK3β pathway is pathologically elevated in the Fragile X model [32]. Suramin inhibited this pathway at several points. Suramin decreased the expression of PI3 Kinase and AKT, and increased the inhibitory phosphorylation of the PI3K/AKT pathway protein glyco- gen synthase kinase 3β (pGSK3βSer9) by 47%. Suramin increased the phosphorylation of p70 S6 kinase (pS6KThr389) by 46% (Figures 3 and 4A-F). Phosphorylated p70 S6KThr389 is a negative regulator of insulin receptor substrate 1 (IRS1), and serves to oppose insulin stimulated cell growth, PI3K, and mTORC1 signaling [33]. We did not find a corresponding change in mTOR expression or phosphorylation in cerebral synaptosomes of the Fragile X model (Additional file 1: Table S1).

Synaptosomal adenomatous polyposis coli (APC) expression

APC is a tumor suppressor protein that is increased in the Fragile X knockout model [34]. APC forms a complex with, and is phosphorylated by, active GSK3β to inhibit microtubule assembly during undifferentiated cell growth of neuronal progenitors [35]. Suramin treatment returned total APC protein to control levels by decreasing expression by 29% (Figure 4G).

Synaptosomal purinergic receptors and the IP3R1 calcium channel

In earlier studies we showed the chronic hyperpurinergia associated with the MIA mouse model resulted in down-regulated expression of the P2Y2 receptor. Suramin treatment in the MIA model increased P2Y2 expression to normal levels [8]. In the Fragile X mouse model, suramin treatment increased the expression of the P2Y1 receptor 32%, and decreased P2X3 receptor expression 18%
There was no effect on P2Y2 expression (Additional file 1: Table S1). P2Y1 signaling is known to inhibit IP3 gated calcium release from the endoplasmic reticulum [36]. We found that suramin treatment was associated with a 101% increase in IP3R1 expression (Figure 4J).

Synaptosomal AMPA receptor (GluR1) expression
AMPA receptor (GluR1) mRNA transcription, translation, and receptor recycling are known to be pathologically dysregulated in the Fragile X model [37]. In the lateral amygdala, the Fragile X knockout results in enhanced internalization and increased internalized receptor pools, with decreased surface expression, such that the total mass of the AMPA receptor is unchanged from controls [38]. Suramin treatment decreased the overall expression of the ionotropic GluR1 in cerebral synaptosomes by 15% (Figure 4K). However, these methods were unable to distinguish between surface and internalized pools of AMPA receptors. Suramin had no effect on metabotropic glutamate receptor mGluR5 expression in this model (Additional file 1: Table S1).

Synaptosomal cannabinoid receptor expression
Cannabinoid signaling is pathologically increased in the Fmr1 knockout model [39]. Suramin treatment decreased brain CB1 receptor expression 16% (Figure 4L). This is consistent with recent data that have shown signaling to be sharply increased in response to brain injury [40]. Pharmacologic blockade with the CB1R antagonist rimonabant has been shown to improve several symptoms in the Fragile X model [41]. CB2 expression is increased in the peripheral blood monocytes of children with autism spectrum disorders [42]. However, CB2 receptor expression in the brain synaptosomes of the Fragile X model was unchanged (Additional file 1: Table S1).

Synaptosomal PPARβ/δ expression
PPARβ (also known as PPARδ) is a widely expressed transcriptional co-activator that is correlated with the aerobic and bioenergetic capacity in a variety of tissue types [43]. Suramin treatment increased the expression of PPARβ/δ in purified brain synaptosomes by 34% (Figure 4M). Suramin treatment had no effect on synaptosomal PPARα (Additional file 1: Table S1).

Synaptosomal cholesterol and bile acid regulatory proteins
Antipurinergic therapy with suramin increased three key proteins involved in sterol and bile acid synthesis. 7-dehydrocholesterol reductase (7DHCR) was increased by 24%, cholesterol 7α-hydroxylase (CYP7A1) by 37%, and the steroidogenic acute regulatory (StAR) protein by 150% (Figure 4N-P) above saline treated control levels. The function of bile salts in the brain is unknown, although their neuroprotective effects have been shown in several models [44,45].

Synaptosomal complement C1q and TDP43
Recent studies have revealed an important role for complement proteins in tagging synapses during inflammation and remodeling [46]. Activated complement proteins have also been found in the brains of children with autism [47].
We found that suramin decreased synaptosomal C1qA by 24% (Figure 4Q).

Tar-DNA binding protein 43 (TDP43) is a single-strand DNA and RNA binding protein that disturbs mitochondrial transport and function under conditions of cell stress [48]. Mutations in TDP43 are associated with genetic forms of amyotrophic lateral sclerosis (ALS) [49]. Wild-type TDP43 protein is a component of the tau and α-synuclein inclusion bodies found in Alzheimer’s and Parkinson’s disease and plays a role in RNA homeostasis.
and protein translation [50]. The similarities of these functions to the role of the \( Fmr1 \) gene in RNA homeostasis prompted us to investigate TDP43 in the Fragile X model. We found that suramin treatment decreased synaptosomal TDP43 by 27% (Figure 4R).

**Synaptosomal amyloid-β precursor protein expression**

Amyloid-β precursor protein (APP) expression is upregulated in the brain of subjects with ASD [51]. A number of recent papers have identified the upregulation of gene networks in ASD [51] and inborn errors of purine metabolism [52] that were formerly thought to be specific for Alzheimer’s and other neurodegenerative disorders. We found that antipurinergic therapy with suramin decreased synaptosomal APP levels by 23% in the Fragile X model (Figure 4S).

**Synaptosomal protein pertinent negatives**

We interrogated the effect of suramin on several additional proteins that were found to be dysregulated in the MIA mouse model [8]. We found no effect of suramin in the Fragile X model on ERK 1 and 2, or its phosphorylation, CAMKII or its phosphorylation, nicotinic acetylcholine receptor alpha 7 subunit (nAChRα7) expression, or the expression of the purinergic receptors P2Y2 and P2X7 (Additional file 1: Table S1). These data show that the detailed molecular effects of antipurinergic therapy with suramin are different in different genetic backgrounds and different mechanistic models of autism spectrum disorders. However, the efficacy in restoring normal behavior and brain synaptic morphology cuts across models. These data support the novel conclusion that antipurinergic therapy is operating by a metabolic mechanism that is common to, and underlies, both the environmental MIA, and the genetic Fragile X models of ASD.

**Metabolomic response to suramin treatment**

We analyzed the metabolomic effects in plasma of Fragile X mice after weekly treatment with suramin or saline. We measured 673 metabolites from 60 pathways by mass spectrometry (Additional file 1: Table S2), analyzed the data by partial least squares discriminant analysis (PLSDA), and visualized the results by projection in three dimensions (Figure 5), and ranked by the metabolic changes by variable importance in projection (VIP) scores (Figure 6). This analysis focused on the rank order of importance. Larger sample sizes, usually \( \geq 15 \) animals per group, are required for more comprehensive metabolomic statistical analysis [53]. We found that suramin produced pharmacometabolic changes in one-third of the biochemical pathways interrogated (20 of 60 pathways). These are summarized below.

![Figure 5](http://www.molecularautism.com/content/6/1/1/)

**Figure 5** Antipurinergic therapy improved the widespread metabolomic abnormalities in the Fragile X mouse model. A total of 673 plasma metabolites from 60 biochemical pathways were measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) and analyzed by partial least squares discriminant analysis (PLSDA). The three top multivariate components were then plotted on x, y, and z-axes, respectively. Suramin treatment shifted metabolism in the direction of wild-type controls. Age 25 weeks, \( N = 9-11 \) per group.
Metabolic pathway analysis

The top 11 of 20 discriminating metabolic pathways were represented by two or more metabolites and contributed 89% of the most discriminating metabolites in the Fragile X mouse model treated with suramin (Table 1). These pathways were: purines (20%), fatty acid oxidation (12%), eicosanoids (11%), gangliosides (10%), phospholipids (9%), sphingolipids (8%), microbiome (5%), SAM/SAH glutathione (5%), NAD\(^+\) metabolism (4%), glycolysis (3%), and cholesterol metabolism (2%) (Table 1).

A simplified map of metabolism is illustrated in the form of 26 major biochemical pathways in Figure 7. This figure shows the effect of suramin treatment on each metabolite as measured in the plasma. The magnitude of the pharmacometabolomic effect is quantified as the z-score for nearly 500 metabolites. Inspection of this figure leads to several conclusions. First, 1-carbon folate and Krebs cycle metabolism are dominated by red shading, indicating a general increase in methylation pathways, and mitochondrial oxidative phosphorylation. Next, there was a generalized increase in intermediates of the SAM/SAH and glutathione (5%), NAD\(^+\) metabolism (4%), glycolysis (3%), and cholesterol metabolism (2%) (Table 1).

Lipid metabolism

Disturbances in lipid metabolism were a prominent feature of the Fragile X mouse model (Additional file 1: Figures S3A-D), and its response to treatment (Table 1, Figure 7). Treatment with suramin produced concerted effects in eight different classes of lipids that collectively explained 54% of the top ranked metabolites identified by multivariate analysis. In rank order of importance these were: fatty acid metabolism (12%), eicosanoid metabolism (11%), ganglioside metabolism (10%), phospholipid metabolism (9%), sphingolipids (8%), microbiome (5%), SAM/SAH glutathione (5%), NAD\(^+\) metabolism (4%), glycolysis (3%), and cholesterol metabolism (2%) (Table 1).

Suramin also had a significant impact on lipid metabolism in the MIA model. Four of the top six metabolic pathways were lipids, explaining 30% of the top ranked VIP scores. In rank order of importance the lipid pathways in the MIA model were: phospholipids (8%), bile acids (8%), sphingolipids (7%), and cholesterol/sterols (7%) [9].
| No. | Pathway name                                                                 | Measured metabolites in the pathway (N) | Expected pathway proportion (P = N/673) | Expected hits in sample of 58 (P * 58) | Observed hits in the top 58 metabolites | Fold enrichment (Obs/Exp) | Impact (Sum VIP score) | Fraction of impact (VIP) explained (% of 136.0) | Suramin treatment effect (KO-Sur/KO-Sal) |
|-----|-------------------------------------------------------------------------------|-----------------------------------------|----------------------------------------|----------------------------------------|------------------------------------------|-------------------------|-----------------------|-----------------------------------------------|----------------------------------------|
| 1   | Purine metabolism                                                             | 41                                      | 0.061                                  | 3.54                                   | 5                                        | 1.41                    | 27.2                   | 20.0%                                         | Increased (4/5)                        |
| 2   | Fatty acid oxidation and synthesis                                            | 39                                      | 0.057                                  | 3.37                                   | 9                                        | 2.67                    | 16.8                   | 12.4%                                         | Decreased (9/9)                        |
| 3   | Eicosanoid and resolvins metabolism                                           | 36                                      | 0.053                                  | 3.11                                   | 6                                        | 1.93                    | 14.7                   | 10.8%                                         | Increased (4/6)                        |
| 4   | Ganglioside metabolism                                                        | 12                                      | 0.018                                  | 1.04                                   | 6                                        | 5.79                    | 13.4                   | 9.8%                                          | Increased (6/6)                        |
| 5   | Phospholipid metabolism                                                       | 115                                     | 0.18                                   | 9.93                                   | 6                                        | 0.60                    | 11.5                   | 8.5%                                          | Increased (6/6)                        |
| 6   | Sphingolipid metabolism                                                       | 72                                      | 0.105                                  | 6.21                                   | 5                                        | 0.80                    | 11.1                   | 8.2%                                          | Decreased (3/3)                        |
| 7   | Microbiome metabolism                                                         | 33                                      | 0.047                                  | 2.85                                   | 3                                        | 1.05                    | 6.7                    | 4.9%                                          | Decreased (2/3)                        |
| 8   | SAM, SAH, methionine, cysteine, glutathione metabolism                        | 22                                      | 0.032                                  | 1.90                                   | 3                                        | 1.58                    | 6.7                    | 4.9%                                          | Increased (3/3)                        |
| 9   | Vitamin B3 (Niacin, NAD+) metabolism                                          | 8                                       | 0.012                                  | 0.69                                   | 2                                        | 2.90                    | 5.2                    | 3.8%                                          | Increased (1/2)                        |
| 10  | Glycolysis and gluconeogenesis                                                | 18                                      | 0.026                                  | 1.55                                   | 2                                        | 1.29                    | 4.2                    | 3.1%                                          | Decreased (2/2)                        |
| 11  | Cholesterol, cortisol, non-gonadal steroid metabolism                         | 29                                      | 0.042                                  | 2.50                                   | 2                                        | 0.80                    | 3.2                    | 2.4%                                          | Increased (2/2)                        |
| 12  | Nitric oxide, superoxide, peroxide, xanthine metabolism                       | 6                                       | 0.009                                  | 0.52                                   | 1                                        | 1.93                    | 2.1                    | 1.5%                                          | Increased (1/1)                        |
| 13  | Cardiolipin metabolism                                                        | 12                                      | 0.018                                  | 1.04                                   | 1                                        | 0.97                    | 2.0                    | 1.4%                                          | Decreased (2/2)                        |
| 14  | Bile salt metabolism                                                          | 8                                       | 0.012                                  | 0.69                                   | 1                                        | 1.45                    | 1.8                    | 1.3%                                          | Increased (1/1)                        |
| 15  | Branch chain amino acid metabolism                                           | 13                                      | 0.019                                  | 1.12                                   | 1                                        | 0.89                    | 1.7                    | 1.2%                                          | Increased (1/1)                        |
| 16  | Isoleucine, valine, threonine, or methionine metabolism                      | 4                                       | 0.006                                  | 0.35                                   | 1                                        | 2.90                    | 1.7                    | 1.2%                                          | Increased (1/1)                        |
| 17  | Pyrimidine metabolism                                                         | 31                                      | 0.051                                  | 2.68                                   | 1                                        | 0.37                    | 1.6                    | 1.1%                                          | Decreased (1/1)                        |
| 18  | Krebs cycle                                                                  | 17                                      | 0.025                                  | 1.47                                   | 1                                        | 0.68                    | 1.6                    | 1.1%                                          | Increased (1/1)                        |
| 19  | Vitamin B6 (pyridoxine) metabolism                                           | 5                                       | 0.007                                  | 0.43                                   | 1                                        | 2.32                    | 1.5                    | 1.1%                                          | Increased (1/1)                        |
| 20  | Pentose phosphate, glucuronate metabolism                                     | 11                                      | 0.016                                  | 0.95                                   | 1                                        | 1.05                    | 1.5                    | 1.1%                                          | Increased (1/1)                        |

Pathways were ranked by their impact measured by summed VIP (%VIP; variable importance in projection) scores. A total of 58 metabolites were found to discriminate suramin-treated and saline-treated Fragile X knockout groups by multivariate partial least squares discriminant analysis (PLSDA). Significant metabolites had VIP scores ≥ 1.5. Twenty (33%) of the 60 pathways interrogated had at least one metabolite with VIP scores ≥ 1.5. The total impact of these 58 metabolites corresponded to a summed VIP score of 136. The fractional impact of each pathway is quantified as the percent of the summed VIP score and displayed in the final column on the right in the table. Antipurinergic therapy with suramin not only corrected purine metabolism, but also produced changes in 19 other pathways associated with multi-system improvements in ASD-like symptoms.
Shared metabolic pathways in the MIA and Fragile X models

We compared the 20 pathways found to be altered in the Fragile X model (Table 1) to the 18 metabolic pathways that were altered in the maternal immune activation (MIA) model [8]. A Venn diagram of this comparison revealed 11 pathways that were shared between these two models (Figure 8). These were purines, the microbiome, phospholipid, sphingolipid, cholesterol, bile acids, glycolysis, the Krebs cycle, NAD\(^+\), pyrimidines, and S-adenosylmethionine (SAM), S-adenosyl-homocysteine (SAH), and glutathione (GSH) metabolism.

Discussion

The Fragile X mouse model is one of the most commonly studied genetic mouse models of ASDs. Using this genetic model, we found that antipurinergic therapy (APT) with suramin improved the behavioral, metabolic, and the synaptic structural abnormalities. We previously showed that the ASD-like symptoms of the maternal immune activation (MIA) mouse model were also improved by antipurinergic therapy [8]. Regardless of the model - whether 'environmental' like the MIA model, or 'genetic' like the Fragile X knockout model - antipurinergic therapy with suramin corrected the abnormalities that characterized each model. Our results support the novel conclusion that antipurinergic therapy is operating by a mechanism that lies close to the root cause of the core behaviors and development in both the environmental MIA, and the genetic Fragile X models of ASD. This mechanism appears to be traceable to mitochondria and regulated by purinergic signaling.
We considered several caveats before drawing these conclusions. The Fragile X knockout mouse model is an imperfect model of human Fragile X syndrome. Human Fragile X syndrome is not the result of knockout of the gene, but rather an expansion of a CGG triplet repeat in the 5’ untranslated region of the gene, and variable phenotypes have been reported in the mouse model [26]. As with many syndromic, single gene disorders, human Fragile X syndrome itself is an imperfect model of non-syndromic ASDs. At least 40% of the boys [55], and over 90% of the girls [56] with Fragile X syndrome do not meet the diagnostic criteria for ASD. We studied the most commonly reported genotype of the Fmr1 knockout mouse model, which was backcrossed for 11 generations on the genetic background of the FVB strain of laboratory mouse. We compared the behavioral features of this Fmr1 knockout to the FVB control strain. A potential weakness of our study is that Fmr1 knockout and FVB control strains are not littermate controls raised by the same mothers. Some behavioral differences might be the result of differences in maternal genotype and rearing. However, the point of our study was not to reconfirm the known behavioral and molecular features of Fragile X model, but rather to ask the question, ‘Are the abnormalities treatable with antipurinergic therapy (APT)?’ Our data suggest that they were.

Other treatments have also been successful in mitigating the symptoms of the Fragile X mouse by addressing specific neurotransmitter or synaptic defects. These have included drug inhibition of glutamatergic signaling with mGluR5 inhibitors [57], inhibition of endocannabinoid signaling [41], and genetic inhibition of amyloid β precursor protein (APP) [58]. A number of metabolic therapies have also been successful. These have included acetyl-L-carnitine [59], omega 3 fatty acid therapy [60], and inhibition of the metabolic control enzyme glycogen synthase kinase 3β (GSK3β) [32]. Remarkably, we found that antipurinergic therapy addressed each of these abnormalities with a single intervention. Minocycline has also shown benefit in both human Fragile X syndrome [61] and mouse models [62]. Interestingly, many of the neuroprotective and anti-inflammatory effects of minocycline have been traced to its actions on mitochondrial function [63,64], and may also act to decrease hyperpurinemia by moderating mitochondrial ATP synthesis.

Purine metabolism was the most discriminating single metabolic pathway in the Fragile X mouse model treated with suramin, contributing 20% of the top ranked metabolites identified by multivariate analysis (Table 1, Figure 7). An important pharmacologic mechanism of action of suramin in the Fragile X mouse model was on purine metabolism (Table 1). Purinergic signaling abnormalities linked to autism-like behaviors are not restricted to animal models. Several inborn errors in purine [15] and pyrimidine metabolism [14] are well known to be associated with autism-like behaviors [9]. In addition, abnormalities in purine metabolism leading to hyperuricosuria in 20% of children with non-syndromic autism have been described [66]. The specific link between purine metabolism in ASD and purinergic signaling was first made in 2012 [67], and tested in the MIA mouse model in 2013 [8]. Interestingly, brain purinergic signaling was recently identified as one of the top gene expression pathways correlated with abnormal behaviors in children with ASD [68].

We next compared the metabolomic results for both the maternal immune activation (MIA) [9] and Fragile X mouse models of ASD (Figure 8). We found 11 metabolic pathways that were common to both models. These were purines, microbiome, phospholipids, sphingolipids/gangliosides, cholesterol/sterol, bile acids, glycolysis, mitochondrial Krebs cycle, NAD+/H, pyrimidines, and S-adenosylmethionine/homocysteine/glutathione (SAM/SAH/GSH) metabolism. Seventeen of the 20 metabolic pathway disturbances found in the Fragile X mouse model have been described in human ASD. These include purine metabolism [15,66], fatty acid oxidation [69], microbiome [70,71], phospholipid [72], eicosanoid [73-75], cholesterol/sterol [76], sphingolipids and gangliosides [77,78], glycolysis, Krebs cycle and mitochondrial metabolism [79-81], nitric oxide and reactive oxygen metabolism [82], branched chain amino acids [83], propionate and propiogenic amino acid metabolism (IVTM; Ile, Val, Thr, Met) [84], pyrimidines [14], SAM/SAH/glutathione [85], vitamin B3-NAD+ metabolism [86], and vitamin B6-pyridoxine metabolism [87]. We found plasma cardiolipin was therapeutically downregulated by suramin. Although elevations in plasma cardiolipin species have not yet been reported in children with autism, anti-cardiolipin antibodies have [88].

The upregulation of glycolysis and downregulation of mitochondrial Krebs cycle seen in the Fragile X model of ASD are a direct consequence of the regulated decrease in mitochondrial oxidative phosphorylation (oxphos). This was corrected by suramin (Figure 7). The conditions of increased substrate supply and decreased utilization, create a poised state of mitochondrial underfunction associated with increased reserve capacity. When basal mitochondrial oxygen consumption is decreased, cellular heat production from mitochondria is reduced. This can lead to a decrease in basal body temperature. We observed a 0.7°C decrease in basal body temperature in the Fragile X mice (Figure 1G). A similar decrease was seen in the MIA mouse model [8]. A poised increase in mitochondrial reserve capacity can also produce primed mitochondria with
the capacity to respond explosively to stress. In some cases, this is manifest as a large increase in mitochondrial reactive oxygen species (ROS) production. Interestingly, an increase in mitochondrial reserve capacity and increased ROS production under stress has been documented in 32% of lymphocytoblastoid cell lines (8/25 = 32%; 95% CI 15-54%) derived from children with ASD [79]. When an explosive discharge of mitochondrial ROS occurs transiently, uncoupling can result, leading to a large increase in mitochondrial heat production and high fevers. Superfevers of 104.5° to 105.5°F have been described in occasional patients with Fragile X during infectious illness (personal communication, Randi J. Hagerman).

When cellular resources are redirected away from work, changes in activity-dependent gene expression result in a reduction in unused proteins [89]. With time these underutilized cells lose the capacity for specific kinds of work and can enter a physiologically-induced hypometabolic state that protects the cell from harsh extracellular conditions and can enter a physiologically-induced hypometabolic state that protects the cell from harsh extracellular conditions and promotes cellular persistence. This state shares metabolic similarities to the dauer state in C. elegans [90], embryonic diapause in mammals [91], plant seed development [92], and stem cells that can be recruited back into cycle after stasis or injury [93]. This latter point suggests that tissues and organs can exist as shifting mosaics of fully active cells, and hypometabolic cells that can be called into action, depending on environmental conditions. In each case, mitochondrial fatty acid oxidation is decreased to facilitate intracellular lipid accumulation needed for persistence metabolism. Fatty acid oxidation was the second most discriminating pathway in the Fragile X mouse model treated with suramin, contributing 12% of the top ranked metabolites identified by multivariate analysis (Table 1, Figure 7). Several acyl-carnitine species were elevated (Table 1, Figure 6). This is a hallmark of diminished mitochondrial fatty acid oxidation [94]. Similar elevations of acyl-carnitines have been reported in 17% of human ASD [69]. Suramin treatment decreased plasma acyl-carnitine levels in the Fragile X model (Figures 6 and 7).

Eicosanoid metabolism was the third most discriminating metabolic pathway in the Fragile X mouse model treated with suramin, contributing 11% of the top ranked metabolites identified by multivariate analysis (Table 1, Figure 7). Eicosanoid metabolism plays a crucial role in regulating the balance of inflammation and anti-inflammation after acute injury, during chronic disease [95,96], and in the antiviral and antibacterial innate immune response [97]. Upregulated lipoxygenase activity in the Fragile X mouse model was recently predicted on the basis of FMRP binding to lipoxygenase mRNA, and disinhibition in the knockout, in a medical hypothesis paper by Beaulieu [75]. The predicted increase in hydroxyeicosatetraenoic acid (HETE) species would support mGluR5-mediated long-term depression (LTD) [98], which is a well-known problem in Fragile X syndrome [99]. We found that suramin treatment increased two epoxyeicosatrienoic acids (EETs), and decreased a stable metabolite of platelet thromboxane A2 (TXA2), 11-dehydro-thromboxane B2 (Figures 6 and 7). The increase in EETs has several physiologic benefits. These include a decrease in ER stress [100], an increase in AMPK activation, and an increase in autophagy [101]. The increase in EETs and decrease in TXA2 were consistent with the anti-inflammatory action of antipurinergic therapy with suramin.

Considered as a coordinated system, these data show that the metabolic disturbances in the mouse models of ASD are similar to those found in human ASD (Figure 8). The data provide strong support for the biochemical validity of both the MIA and Fragile X mouse models. In addition, the metabolomics data revealed for the first time the surprising observation that the environmental MIA and the genetic Fragile X mouse models, and human ASD, all shared disturbances in biochemical pathways previously identified as features of the evolutionarily conserved cell danger response (CDR) (Figure 8) [54]. We found that in the mouse models, both the ASD-like symptoms and the biochemical features of the CDR were corrected by antipurinergic therapy with suramin.

Purinergic signaling begins with the regulated release of purine nucleotides like ATP, or pyrimidines like UTP, through channels in the cell membrane for autocrine and paracrine signaling, and by vesicular fusion during neurotransmission [102,103]. Purinergic (P2X and P2Y) receptors bind to extracellular ATP and other nucleotides as a means of sensing cellular health and danger [54,104]. In this usage, the word ‘danger’ is not an anthropomorphic construct. Danger has a chemical meaning in cells that equates to metabolic mismatches between substrate/product ratios and the gene-coded and allosterically regulated equilibrium constant ($K_{eq}$) of each relevant enzyme located in mitochondria, and the conductances of transporters in and out of the organelles [105]. These mismatches are coupled to mitochondrial oxygen consumption, electron flow, redox, and oxidative phosphorylation, and produce a sequence of graded metabolic responses that alter DNA methylation [106], histone modifications [107], and lead to new cellular states of gene expression and function [108]. In most differentiated cells, mitochondria make 90% of the ATP, and process 90% of the carbon skeletons and activated sulfur intermediates used to create the building blocks for cell growth, function, detoxification, and repair. Mitochondria serve as the cellular translators of real-time metabolic information, integrating it with the genetics of the cell, and providing feedback in the form of retrograde signals to the nucleus [109] used to change gene expression.
When extracellular ATP binds to purinergic receptors on the cell surface it is participating in what we call a ‘long-path’ retrograde signaling circuit from mitochondria to the unstirred water layer on the cell surface, to neighboring cells, or back through autologous cell membrane G-protein coupled receptors and ion channels, to calcium signaling, back to mitochondria and other cellular compartments, and ultimately to the nucleus, changing gene expression. This extracellular purinergic signaling circuit is well known to regulate innate immunity, oxidative stress and shielding [110], inflammation, and cytokine production [104], sensory perception [111], in addition to sleep, cognition [112], and the autonomic nervous system [113]. Intracellular adenine nucleotides like NAD+/H, NADP+/H, cyclic-ADP-ribose (cADPR), and nicotinic acid adenine dinucleotide phosphate (NAADP) are also traceable to mitochondria, are interconverted by the enzyme CD38 [114], and play important roles in a ‘short-path’ retrograde signaling circuit that regulates redox, calcium release, sodium and potassium channels [115], synaptic long-term depression [116], autophagy [117], defense against intracellular pathogens [118], and social behavior by modulating oxytocin secretion [119]. These studies underscore the surprising role of extracellular and intracellular purines in regulating a diverse array of biological phenomena, ranging from innate immunity and cellular defense, to sleep, cognition, behavior, perception, affect, memory, and learning.

Although our results showing the correction of ASD-like behaviors, and improvements in metabolism and brain synaptic abnormalities in the Fragile X mouse model are encouraging, there are several caveats that must be considered before extending the results to humans. First, while the Fragile X mouse model captures several features of ASD, no animal model can fully capture the complexities of human behavior. Second, suramin is a poor drug choice for chronic use because of potentially toxic side effects that can occur with prolonged treatment [120]. Third, human forms of ASD may occur by mechanisms not captured by the Fragile X model. Mechanisms that do not involve the pathological persistence of the cell danger response (CDR) [54] may not be amenable to antipurinergic therapy. Newer, safer, more selective antipurinergic drugs, and human clinical trials will be necessary to answer these questions.

**Conclusions**

The data reported in this study show that the efficacy of antipurinergic therapy cuts across disease models of ASD. Both the environmental MIA [8,9] and the genetic Fragile X mouse models (Figures 1, 2, 3, 4, 5, 6, 7, 8, Tables 1 and 2) responded with complete, or near-complete, resolution of symptoms, even when treatment was not begun until adolescence, or adulthood. The data support the hypothesis that disturbances in purinergic signaling may be a common denominator and effective therapeutic target in both the environmental MIA and genetic Fragile X mouse models of autism spectrum disorders.

**Additional file**

Additional file 1: This supplement includes a single PDF file with: supplementary Results, Methods, References, three tables, and four figures. Figure S1. Confirmation of Fragile X protein expression knockout in the Fmr1/FVB Mouse Model. Figure S2. Acoustic startle and prepulse inhibition. Figure S3. Acyl-carnitine studies in Fmr1 knockout mouse models. Figure S4. Western blot assay linearity and precision analysis. Table S1. Synaptic proteins interrogated and antibodies used. Table S2. Biochemical pathways and metabolites interrogated. Table S3. Metabolites changed by antipurinergic therapy in the Fragile X model.
Abbreviations
APP: Amyloid β precursor protein; APT: Antipurinergic therapy; ASD: Autism spectrum disorders; C1q: Complement factor 1 subunit q; CDR: Cell danger response; Fmr1: Fragile X mental retardation gene locus 1; IP3: Inositol trisphosphate; MIA: Maternal immune activation; P2X2: Ionotropic purinergic receptors; P2Y2: G-protein coupled purinergic receptors; TDP43: TAR DNA binding protein 43.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JCN coordinated the study, conducted the experiments, analyzed the data, and wrote parts of the manuscript. KL and JCN did the metabolomics. LW helped prepare the synaposomes, processed them for electron microscopy, and did the western studies. ATB developed the bioinformatic tools for metabolomics data processing and visualization in Cytoscape. WAA helped with the Cytoscape analysis and helped write the manuscript. KRW started the metabolic pathway renderings in Cytoscape. SBP directed the behavioral studies and their analysis. RKN assembled the team, designed, funded and directed the project, analyzed the data, and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments
This research was supported by grants from the Jane Botsford Johnson Foundation (RKN), with additional support from the UCSD Christini Foundation, the UCSD Mitochondrial Research Fund, and the Wright Family Foundation (RKN), with additional support from the UCSD Christini Foundation to RKN. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author details
1The Mitochondrial and Metabolic Disease Center, University of California, San Diego School of Medicine, 214 Dickinson St, Bldg CTF, Rm C102, San Diego, CA 92103-8467, USA. 2Department of Medicine, University of California, San Diego School of Medicine, 214 Dickinson St, Bldg CTF, Rm C102, San Diego, CA 92103-8467, USA. 3Department of Pediatrics, University of California, San Diego School of Medicine, 214 Dickinson St, Bldg CTF, Rm C102, San Diego, CA 92103-8467, USA. 4Department of Pathology, University of California, San Diego School of Medicine, 214 Dickinson St, Bldg CTF, Rm C102, San Diego, CA 92103-8467, USA. 5Department of Psychiatry, University of California, San Diego School of Medicine, 214 Dickinson St, Bldg CTF, Rm C102, San Diego, CA 92103-8467, USA. 6Research Service, VA San Diego Healthcare System, La Jolla, CA, USA. 7Veterans Affairs Center for Excellence in Stress and Mental Health (CESAMH), La Jolla, CA, USA. 8Current Address of KRW: General Atomics, Inc, San Diego, CA, USA.

Received: 8 September 2014 Accepted: 16 December 2014
Published: 13 January 2015

References
1. Developmental Disabilities Monitoring Network Surveillance Year Principal I, Centers for Disease C, Prevention. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ. 2011;60:1–21.
2. Anney R, Klei L, Pinto D, Almeida J, Bacchelli E, Baird G, et al. Individual common variants exert weak effects on the risk for autism spectrum disorders. Hum Mol Genet. 2012;21:4781–792.
3. Pinto D, Fagmumenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466:368–372.
4. Casey JP, Magalhaes T, Conroy JM, Regan R, Shah N, Anney R, et al. A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet. 2012;131:565–579.
5. Volk HE, Lurmann F, Penfold B, Hertz-Picciotto I, McConnell R. Traffic-related air pollution, particulate matter, and autism. JAMA Psychiatry. 2013;70:71–77.

6. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Tonge T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry. 2011;68:1095–1102.
7. Krakowiak P, Walker CK, Bremer AA, Baker AS, Ozonoff S, Hansen RL, et al. Maternal metabolic conditions and risk for autism and other neurodevelopmental disorders. Pediatrics. 2012;129(1):1121–1128.
8. Naviaux RK, Zebkili-Cunningham Z, Nakayama T, Naviaux JC, Le T, Wang L, et al. Antipurinergic therapy corrects the autism-like features in the Poly(IC) mouse model. PloS One. 2013;8:e57380.
9. Naviaux JC, Schuchmann UA, Li K, Wang L, Risbrough VB, Powell SB, et al. Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl Psychiatry. 2014;4:e400.
10. Chen E, Sharma MR, Shi X, Agrawal RK, Joseph S. Fragile X mental retardation protein regulates translation by binding directly to the ribosome. Mol Cell. 2014;54:407–417.
11. Alpatov R, Lesch BJ, Nakamoto-Kinoishita M, Blanco A, Chen S, Stutzer A, et al. A chromatin-dependent role of the fragile X mental retardation protein FMRP in the DNA damage response. Cell. 2014;157:869–881.
12. Bogin C, Tassone F, Nerl G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012;122:4314–4322.
13. Bakker CE, Verheij C, Willemsen R, van der Helm R, Oerlemans F, Verme Y, et al. Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell. 1994;79:23–33.
14. Micheli V, Covic M, Tozzi MG, Iapal S, Sestini S, Bertelli M, et al. Neurological disorders of purine and pyrimidine metabolism. Curr Top Med Chem. 2011;11:923–947.
15. Nyhan WL, James JA, Teberg AJ, Sweetman LG. A new disorder of purine metabolism with behavioral manifestations. J Pediatr. 1969;74:220–227.
16. Light AR, Wu Y, Hughes RW, Guthrie PB. Purinergic receptors activating rapid intracellular Ca increases in microglia. Neuron Glia Biol. 2006;6:125–138.
17. Dunn PM, Bleskcy AE, Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens. Br J Pharmacol. 1989;93:243–245.
18. McGaey RP, Bennett AJ, Tian QB, Cogrove KL, Ross BP, Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem. 2008;8:1384–1394.
19. Moy SS, Nadler JJ, Young NB, Nonneman RJ, Segall SK, Andrade GM, et al. Social approach and repetitive behavior in eleven inbred mouse strains. Behav Brain Res. 2008;191:118–129.
20. Thomas A, Buntar A, Bui N, Graham D, Yuwa-Paylor LA, Paylor R. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl). 2009;204:361–373.
21. Halberstard AL, van der Heijden I, Rudeerman MA, Ridrough VB, Gingrich JA, Geyer MA, et al. 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology. 2009;34:1958–1967.
22. Asp L, Holdez M, Powell SB, Karlsson H, Ehrhardt S. Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1−/− mice. Int J Neuropsychopharmacol. 2010;13:475–485.
23. Adrian Bouwmeester J, Olivier B, Paylor RE. The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse. Neurosci Biobehav Rev. 2007;31:41–59.
24. Golde WT, Collobin P, Rodriguez LL. A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim. 2005;34:39–43.
25. Xia J, Mandal R, Shennikov IV, Broadhurst D, Wishart DS. MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012;40:W127–133.
26. Budimirovic DB, Kaufmann WE. What can we learn about autism from studying fragile X syndrome? Dev Neurosci. 2011;33:379–394.
27. Hughes RN. Neotic preferences in laboratory rodents: issues, assessment and substrates. Neurosci Biobehav Rev. 2007;31:441–464.
28. Vecera SP, Rothbart MK, Posner MI. Development of spontaneous alternation in infancy. J Cogn Neurosci. 1991;3:351–354.
29. Munson J, Faja S, Melzoff A, Abbott R, Dawson G. Neurocognitive predictors of social and communicative developmental trajectories in preschoolers with autism spectrum disorders. J Int Neuropsychol Soc. 2008;14:956–966.
30. Godham K, Bishop SL, Hus V, Huta M, Lund S, Buja A, et al. Exploring the relationship between anxiety and insistence on sameness in autism spectrum disorders. Autism Res. 2013;6:33–41.
31. Moy SS, Nadler JJ, Young NB, Perez A, Holloway LP, Barbano RP, et al. Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. Behav Brain Res. 2007;176:264–270.
32. Franklin AV, King MK, Palomo V, Martinez A, McMahon LL, Jope RS. Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Biol Psychiatry. 2014;75:198–206.
33. Fenton TR, Gout IT. Functions and regulation of the 70kDa ribosomal S6 kinases. J Biol Chem. 2011;286:47–59.
34. Liao L, Park SK, Xu T, VanderKlish P, Yates 3rd JR. Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc Natl Acad Sci U S A. 2008;105:15281–15286.
35. Arevalo JC, Chao MV. Axonal growth: where neurotrophins meet Wnts. Curr Opin Cell Biol. 2005;17:112–115.
36. MacMillan D, Kennedy C, McCarnon JG. ATP inhibits Ins(1,4,5)P3-evoked Ca2+ release in smooth muscle via FY11 receptors. J Cell Sci. 2012;125:1511–18.
37. Muddashetty RS, Keel S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. Neurobiol. 2007;27:5338–5348.
38. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A. 2010;107:11591–6.
39. Straker A, Min KT, Mackie K. Fmr1 deletion enhances and ultimately desensitizes CB1 signaling in autaptic hippocampal neurons. Neurobiol Dis. 2013;56:3–15.
40. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids targeting the endocannabinoid system in the treatment of fragile X syndrome. Brain Dev. 2013;34:147–155.
41. Busquets-Garcia A, Gomis-Gonzalez M, Guegan T, Agustin-Pavon C, Pastor A, Naviaux R. Altered expression of Alzheimer disease-associated mutant TDP-43 impairs mitochondrial dynamics and localization of TDP-43 immunoreactivity in the anterior horns in sporadic neuroglial activation and neuroinflammation in the brain of patients with Alzheimer's disease. J Biol Chem. 2005;280:42655–42668.
42. Vess R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic alterations of brain activity and improves cognitive performance in fragile X mice. Proc Natl Acad Sci U S A. 2013;110;56:129–131.
43. MacMillan D, Kennedy C, McCarron JG. ATP inhibits Ins(1,4,5)P3-evoked Ca2+ release in smooth muscle via FY11 receptors. J Cell Sci. 2012;125:1511–18.
44. Mortiboys H, Aasly J, Bandmann O. Ursocholanic acid rescues mitochondrial dysfunction caused by minocycline in cerebellar granule cells. Biochem Pharmacol. 2010;79:239–250.
45. Lambrecht G, Braun K, Damer M, Ganso M, Hildebrandt C, Ullmann H, et al. Structure-activity relationships of susrmanin and pyridoxal-5’-phosphate derivatives as P2 receptor antagonists. Curr Pharm Des. 2002;8:2371–2379.
46. Page T, Coleman M. Purine metabolism abnormalities in a hyperuricosuric subclass of autism. Biochem Biophys Acta. 2000;1511:297–311.
47. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. Neurobiol. 2007;27:5338–5348.
48. Fenton TR, Gout IT. Functions and regulation of the 70kDa ribosomal S6 kinases. J Biol Chem. 2011;286:47–59.
49. Liao L, Park SK, Xu X, VanderKlish P, Yates 3rd JR. Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc Natl Acad Sci U S A. 2008;105:15281–15286.
50. Arevalo JC, Chao MV. Axonal growth: where neurotrophins meet Wnts. Curr Opin Cell Biol. 2005;17:112–115.
51. MacMillan D, Kennedy C, McCarron JG. ATP inhibits Ins(1,4,5)P3-evoked Ca2+ release in smooth muscle via FY11 receptors. J Cell Sci. 2012;125:1511–18.
52. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. Neurobiol. 2007;27:5338–5348.
53. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A. 2010;107:11591–6.
54. Straker A, Min KT, Mackie K. Fmr1 deletion enhances and ultimately desensitizes CB1 signaling in autaptic hippocampal neurons. Neurobiol Dis. 2013;56:1–5.
55. Shahni E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids targeting the endocannabinoid system in the treatment of fragile X syndrome. Brain Dev. 2013;34:147–155.
56. Page T, Coleman M. Purine metabolism abnormalities in a hyperuricosuric subclass of autism. Biochem Biophys Acta. 2000;1511:297–311.
57. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. Neurobiol. 2007;27:5338–5348.
58. Fenton TR, Gout IT. Functions and regulation of the 70kDa ribosomal S6 kinases. J Biol Chem. 2011;286:47–59.
59. Liao L, Park SK, Xu X, VanderKlish P, Yates 3rd JR. Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc Natl Acad Sci U S A. 2008;105:15281–15286.
60. Arevalo JC, Chao MV. Axonal growth: where neurotrophins meet Wnts. Curr Opin Cell Biol. 2005;17:112–115.
61. Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr. 2013;34:147–155.
62. Dansie LE, Phommahaxay K, Okusanya AG, Uwadia J, Huang M, Rotschafer SE, et al. Long-lasting effects of minocycline on behavior in young but not adult fragile X mice. Neuroscience. 2013;246:185–198.
63. Kim HS, Suh HY. Minocycline and neurodegenerative diseases. Behav Brain Res. 2019;369:168–179.
64. Garcia-Martinez EM, Sanz-Blasco S, Karachtos A, Bandzo MJ, Fernandez-Gomez FJ, Perez-Alvarez S, et al. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol. 2010;79:239–250.
65. Lambrecht G, Braun K, Damer M, Ganso M, Hildebrandt C, Ullmann H, et al. Structure-activity relationships of susrmanin and pyridoxal-5’-phosphate derivatives as P2 receptor antagonists. Curr Pharm Des. 2002;8:2371–2379.
66. Page T, Coleman M. Purine metabolism abnormalities in a hyperuricosuric subclass of autism. Biochem Biophys Acta. 2000;1511:297–311.
67. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. Neurobiol. 2007;27:5338–5348.
68. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A. 2010;107:11591–6.
69. Straker A, Min KT, Mackie K. Fmr1 deletion enhances and ultimately desensitizes CB1 signaling in autaptic hippocampal neurons. Neurobiol Dis. 2013;56:1–5.
70. Shahni E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids targeting the endocannabinoid system in the treatment of fragile X syndrome. Brain Dev. 2013;34:147–155.
71. Page T, Coleman M. Purine metabolism abnormalities in a hyperuricosuric subclass of autism. Biochem Biophys Acta. 2000;1511:297–311.
72. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. Neurobiol. 2007;27:5338–5348.
73. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A. 2010;107:11591–6.
74. Straker A, Min KT, Mackie K. Fmr1 deletion enhances and ultimately desensitizes CB1 signaling in autaptic hippocampal neurons. Neurobiol Dis. 2013;56:1–5.
lymphoblastoid cell lines in a well-matched case control cohort. PLoS One. 2014;9:e85436.
10. Graf WD, Marin-Garcia J, Giao HG, Pizzo S, Naviaux RK, Markusd C, et al. Autism associated with the mitochondrial DNA G8363A transfer RNA(Lys) mutation. J Child Neurol. 2000;15:357–361.
11. Smith M, Fridman PL, Gargus JJ, Simon MT, Venell K, Haas R, et al. Mitochondrial and ion channel gene alterations in autism. Biochim Biophys Acta. 1817;2012:1796–802.
12. Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, Dalla Bernardina B, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med. 2012;52:2128–141.
13. Tiurovanziam R, O'Okhanyanch T, Laval J, Aronov PA, Libove R, Banerjee AG, et al. Distinct plasma profile of polar neutral amino acids, leucine, and glutamate in children with autism spectrum disorders. J Autism Dev Disord. 2014;42:827–836.
14. Al-Owain M, Kaya N, Al-Shamrani H, Al-Bakheet A, Qari A, Al-Muaisig S, et al. Autism spectrum disorder in a patient with propionic acidemia. JIMD Rep. 2013;7:63–65.
15. James SJ, Melnych S, Jerimigan S, Hubanks A, Rose S, Gaylor DW. Abnormal transmethylation/transsulfuration metabolism and DNA hypomethylation among parents of children with autism. J Autism Dev Disord. 2008;38:176–184.
16. Essa MM, Subash S, Brandy N, Al-Adawi S, Lim CK, Vinvasagam T, et al. Role of NAD(+), oxidative stress, and tryptophan metabolism in autism spectrum disorders. Int J Tryptophan Res. 2013;6:15–28.
17. Adams JB, George F, Audhya T. Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements. J Aliment Complement Med. 2006;12:59–63.
18. Careaga M, Hansen RL, Hertz-Picottto I, Van de Water J, Ashwood P. Increased antiphospholip antibodies in autism spectrum disorders. Mediators Inflamm. 2013;2013:935608.
19. Hermy G, Malicke H, Gutzmann JJ, Schreiber J, Bluthgen N, Kuhl D. Genome-wide profiling of the activity-dependent hippocampal transcriptome. PLoS One. 2013;8:e76903.
20. Lant B, Storey KM. Metabolic rate depression in animals: transcriptional and translational controls. Biol Rev Camb Philos Soc. 2004;79:207–233.
21. Schwender J, Shachar-Hill Y, Ohligoee JB. Mitochondrial metabolism in developing embryos of Brassica napus. J Biol Chem. 2006;281:34040–34047.
22. Naviaux RK, Le TP, Beldabea K, Leferovich J, Gourevitch D, Sachadyn P, et al. Regulation of ion channels and protectin formation. Prostaglandins Other Lipid Mediat. 2012;97:73–82.
23. Careaga M, Hansen RL, Hertz-Picottto I, Van de Water J, Ashwood P. Increased antiphospholip antibodies in autism spectrum disorders. Mediators Inflamm. 2013;2013:935608.
24. Hermy G, M{"a}liche H, Gutzmann JJ, Schreiber J, Bluthgen N, Kuhl D. Genome-wide profiling of the activity-dependent hippocampal transcriptome. PLoS One. 2013;8:e76903.
25. Lant B, Storey KM. Metabolic rate depression in animals: transcriptional and translational controls. Biol Rev Camb Philos Soc. 2004;79:207–233.
26. Schwender J, Shachar-Hill Y, Ohligoee JB. Mitochondrial metabolism in developing embryos of Brassica napus. J Biol Chem. 2006;281:34040–34047.
27. Naviaux RK, Le TP, Beldabea K, Leferovich J, Gourevitch D, Sachadyn P, et al. Retained features of embryonic metabolism in the adult MRL mouse. Mol Genet Metab. 2009;96:133–144.
28. Vreken P, van Lint AE, Bootse HA, Overmars W, Randers JW, van Gennip AH. Rapid diagnosis of organic acidoses and fatty acid oxidation defects by quantitative electrospray tandem-MS acyl-carnitine analysis in plasma. Adv Exp Med Biol. 1999;466:327–337.
29. Weylandt KH, Chiu CY, Gomolka B, Waechter SF, Wiedemann B. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat. 2012;97:73–82.
30. Hammond VJ, O’Donnell VB. Estified eicosanoids: classification, characterization and function. Biochim Biophys Acta. 1818;2012;2403–2412.
31. Le Bel M, Brunet A, Gosselin J, Lekotriene BA, an endogenous stimulator of the innate immune response against pathogens. J Innate Immun. 2014;6:159–168.
32. Feinmark SJ, Begun R, Tsvetkov E, Goussakov I, Funk CD, Siegelbaum SA, et al. 12-lipoxygenase metabolites of arachidonic acid mediate metabolic glutamate receptor-dependent long-term depression at hippocampal CA3-CA1 synapses. J Neurosci. 2003;23:11427–11435.
33. Chen T, Lu JS, Song Q, Liu MG, Koga K, Desalci G, et al. Pharmacological rescue of cortical synaptic and network potentiation in a mouse model for fragile x syndrome. Neuropsychopharmacology. 2014;39:1955–1967.
34. Wang X, Ni L, Yang L, Duan Q, Chen C, Edin ML, et al. CYP2J2-derived epoxyeicosatrienoic acids suppress endoplasmic reticulum stress in heart failure. Mol Pharmacol. 2014;85:105–115.
35. Samokhvalov V, Alsaleh N, Al-Adawi S, Lopatina O, Higashida C, Tsuji T, et al. Locomotor activity, ultrasonic vocalization and oxytocin levels in infant CD38 knockout mice. J Biol Chem. 2012;287:31633–31640.
36. Kilfoil P, Tipparaju SM, Banski OA, Bhaitnagar A. Regulation of ion channels by pyridine nucleotides. Circ Res. 2013;112:721–741.
37. Reyes-Harde M, Empson R, Potter BV, Gallone A, Stanton PK. Evidence of a role for cyclic ADP-ribose in long-term synaptic depression in hippocampus. Proc Natl Acad Sci U S A. 1999;96:4061–4066.
38. Parrington J, Tunn R. Ca(2+) signals, NAADP and two-pore channels: role in cellular differentiation. Acta Physiol (Oxf). 2014;211:285–296.
39. Lischke T, Heesch K, Schumacher V, Schneider M, Haag F, Koch-Nothe F, et al. CD38 controls the innate immune response against Listeria monooyctogenes. Infect Immun. 2013;81:4009–4019.
40. Liu HX, Lopatina O, Higashida C, Tsuji T, Kato I, Takasaki S, et al. Locomotor activity, ultrasonic vocalization and oxytocin levels in infant CD38 knockout mice. Neurosci Lett. 2008;446:57–70.
41. Voogd TE, Vansterkenburg EL, Witting J, Janssen LH. Recent research on the biological activity of suramin. Pharmacol Rev. 1993;45:177–203.

Cite this article as: Naviaux et al.: Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model. Molecular Autism 2015 6:1.